Harel Insurance Investments & Financial Services Ltd., a registered investment adviser, reduced its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during Q3 2026,…
01Harel Insurance reduced its Teva Pharmaceutical stake by 28%, selling 13.5 million shares and keeping 34.7 million shares worth approximately $1.4 billion.
02Teva Pharmaceutical trades at $41.55 per share with a $34.6 billion market capitalization as of the filing date.
03The $1.37 billion position remains among significant institutional holdings, though large sales can influence trading dynamics.
0413F filings show holdings as of quarter-end and are filed up to 45 days later, so actual positions may differ from reported data.
Filing Details
Harel Insurance Investments & Financial Services Ltd., a registered investment adviser, reduced its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) during Q3 2026, according to its most recent 13F filing with the Securities and Exchange Commission.
The firm sold 13,483,390 shares of the Healthcare company, reducing its total holdings to 34,655,415 shares valued at approximately $1.4B as of the filing date. This represents a 28.0% decrease in the position.
Market Context
Teva Pharmaceutical Industries Limited's stock currently trades at $41.55 with a market capitalization of $34.6B.
Institutional selling doesn't always signal a bearish outlook. Large funds regularly trim positions for portfolio rebalancing, client redemptions, or to lock in gains. That said, when a major holder like Harel Insurance Investments & Financial Services Ltd. reduces exposure to Teva Pharmaceutical Industries Limited, it's worth monitoring whether other institutions are making similar moves.
Healthcare stocks have attracted institutional attention as an aging population drives long-term demand. Teva Pharmaceutical Industries Limited operates in a sector where regulatory developments and pipeline progress can significantly impact institutional positioning.
The size of this position — $1.37 billion — places it among the more significant institutional holdings in Teva Pharmaceutical Industries Limited. Large positions like this can influence trading dynamics and are closely watched by market participants tracking smart money flows.
Investors should note that 13F filings reflect holdings as of the end of the reporting quarter and are filed up to 45 days later. The position may have changed since the filing date. 13F data is most useful when analyzed alongside other signals such as insider transactions, analyst ratings, and fundamental trends.
A 13F filing is a quarterly SEC report required for institutional managers with over $100 million in assets. It discloses equity holdings, providing transparency into how firms like Harel Insurance Investments & Financial Services Ltd. position their portfolios.